No Data
No Data
Express News | Amgen UK: Imdylltra Granted Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in UK
Amgen's IMDYLLTRA▼ (Tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom
These 4 Measures Indicate That Amgen (NASDAQ:AMGN) Is Using Debt Extensively
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer